Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

5.10USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
156,949
52-wk High
$14.09
52-wk Low
$4.77

Latest Key Developments (Source: Significant Developments)

Nabriva Therapeutics Announces Completion Of Enrollment In Leap 2, A Phase 3 Clinical Trial Evaluating Oral Lefamulin
Monday, 4 Dec 2017 07:00am EST 

Dec 4 (Reuters) - Nabriva Therapeutics Plc ::NABRIVA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN LEAP 2, A PHASE 3 CLINICAL TRIAL EVALUATING ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA IN ADULTS.NABRIVA THERAPEUTICS PLC - ‍ANTICIPATES TOPLINE CLINICAL RESULTS FROM LEAP 2 TO BE AVAILABLE IN SPRING OF 2018​.  Full Article

Nabriva Therapeutics reports Q3 loss per share $0.79
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Nabriva Therapeutics Plc :Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.79.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Nabriva - On track to complete patient enrollment for second phase 3 trial, leap 2, before year end 2017, & expects topline results in spring 2018​.Nabriva Therapeutics Plc - ‍$112.7 million cash and investments as of September 30, 2017​.Nabriva Therapeutics Plc - ‍Cash balance is expected to fund operations into Q4 of 2018​.  Full Article

Nabriva therapeutics announces positive topline results
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Nabriva Therapeutics PLC :Nabriva Therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia.Nabriva Therapeutics PLC - ‍lefamulin met all primary FDA and EMA endpoints with a favorable tolerability profile​.Nabriva - ‍in leap 1 trial, similar rate of treatment-emergent adverse events observed in lefamulin arm and moxifloxacin with or without linezolid arm​.Nabriva Therapeutics PLC - ‍company expects to complete enrollment in Q4 of 2017, and to have topline data available in spring of 2018 for leap 2​.Nabriva Therapeutics PLC - ‍death occurred with similar frequency in both lefamulin arm and moxifloxacin with or without linezolid arm​.Nabriva Therapeutics PLC - ‍6 patients died in lefamulin arm and 5 patients died in moxifloxacin with or without linezolid arm​.  Full Article

Nabriva Therapeutics reports Q2 loss per share $0.54
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Nabriva Therapeutics Plc :Nabriva Therapeutics reports second quarter 2017 financial results and recent corporate highlights.Q2 loss per share $0.54.  Full Article

Nabriva Therapeutics files for mixed shelf of upto $175 mln - SEC Filing
Friday, 28 Jul 2017 05:20pm EDT 

July 28 (Reuters) - Nabriva Therapeutics Plc :Files for mixed shelf of upto $175 million - SEC Filing.  Full Article

Nabriva Therapeutics reports Q1 loss per share $5.60
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Nabriva Therapeutics AG :Nabriva Therapeutics reports first quarter 2017 financial results.Q1 loss per share $5.60.  Full Article

Nabriva Therapeutics says supervisory, management board approves relocation of holding co of Nabriva AG, subsidiaries to Ireland
Monday, 17 Apr 2017 07:00am EDT 

April 17 (Reuters) - Nabriva Therapeutics AG ::Nabriva Therapeutics AG - supervisory board, management board approved relocation of holding co of Nabriva AG, subsidiaries from Austria to Ireland.Nabriva Therapeutics AG - redomiciliation transaction will be effected by exchange of ADSS of Nabriva AG for shares of Nabriva Therapeutics Plc.Nabriva Therapeutics- expected Nabriva Ireland will become publicly-traded parent co of Nabriva Group, subsidiaries with tax residency in Ireland.  Full Article

Nabriva Therapeutics announces enrollment completion for a phase 3 clinical trial evaluating lefamulin in community-acquired bacterial pneumonia
Tuesday, 11 Apr 2017 07:00am EDT 

Nabriva Therapeutics Ag : Nabriva Therapeutics announces enrollment completion for Leap 1, a phase 3 clinical trial evaluating lefamulin in community-acquired bacterial pneumonia .Nabriva Therapeutics AG - Company anticipates availability of top-line clinical data from Leap 1 in Q3 of 2017.  Full Article

Nabriva Therapeutics provides business and development update and reports 2016 financial results
Friday, 24 Mar 2017 04:05pm EDT 

Nabriva Therapeutics AG : Nabriva Therapeutics provides business and development update and reports 2016 financial results . Nabriva Therapeutics AG- Expect to complete patient enrollment for leap 2 in Q4 of 2017 . Nabriva Therapeutics AG- Anticipate receiving top-line data for leap 2 in Q1 of 2018 .Nabriva Therapeutics AG - Expect year-end balance will be sufficient to fund our operating expenses and capital expenditures at least into Q2 of 2018.  Full Article

Nabriva Therapeutics anticipate topline data from phase 3 trials in second half of 2017
Thursday, 2 Feb 2017 07:00am EST 

Nabriva Therapeutics AG : Nabriva therapeutics confirms no sample size adjustment required for leap 1 phase 3 trial of lefamulin in community acquired bacterial pneumonia . Nabriva therapeutics ag- expects to announce topline leap 1 data by end of q3 of 2017 . Nabriva therapeutics - expects to complete leap 1 enrollment of about 550 patients with moderate, severe community-acquired bacterial pneumonia in q2 of 2017 .Nabriva therapeutics ag - anticipate topline clinical data from both of global, registrational cabp phase 3 trials in second half of 2017.  Full Article

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights